This website is intended for US residents.

For Healthcare Providers
Real EKTERLY® (sebetralstat) patient Cari enjoying a day out with her husband Real EKTERLY® (sebetralstat) patient Cari enjoying a day out with her husband
Real EKTERLY® (sebetralstat) patient Zach happily conversing with a friend Real EKTERLY® (sebetralstat) patient Zach happily conversing with a friend
Real EKTERLY® (sebetralstat) patient Ellis at football practice with his mother, Hortencia Real EKTERLY® (sebetralstat) patient Ellis at football practice with his mother, Hortencia
Real EKTERLY® (sebetralstat) patient Mistie enjoying her conversation with her daughters Real EKTERLY® (sebetralstat) patient Mistie enjoying her conversation with her daughters
Real EKTERLY® (sebetralstat) patient Jason peacefully tightening a tool in his workshop Real EKTERLY® (sebetralstat) patient Jason peacefully tightening a tool in his workshop

Real Results. Real Patients.

Hear stories of patient experiences
with EKTERLY—
the first and only
oral on-demand HAE treatment.

Discover EKTERLY Patient Stories
Real EKTERLY patient

Select which best applies to you:

Newly diagnosed with HAE Recently learned about EKTERLY Thinking about switching
treatments

An oral acute treatment that can go wherever you do

EKTERLY provides rapid relief from HAE attacks, with a median time of 1.8 hours to beginning of symptom relief.*

HAE attack locations

Effective against all
types of attacks
whether
you’re on preventative
therapy or not.

Timer

Proven to begin
providing symptom
relief fast.

Shield

Safety events
were similar to
placebo.†

See proven results

*Analysis does not include attacks where response information was not provided. In product label, these attacks were included as having no response to treatment at 12 hours, shifting median to 2.0 hours.

†The most common side effects of EKTERLY include headache.

Support at every step

Our patient support program is
dedicated to ensuring you have the
treatment you need when you need it.

Learn more about getting EKTERLY
Calendar

Learn more at EKTERLY Educational Events

Connect with healthcare professionals and hear firsthand experiences from people living with HAE at free virtual and in-person programs.

Find a program

INDICATION AND IMPORTANT SAFETY INFORMATION

WHAT IS EKTERLY® (sebetralstat)?

EKTERLY is a prescription medicine used to treat sudden (acute) attacks of hereditary angioedema (HAE) in adults and children aged 12 years of age and older. It is not known if EKTERLY is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if EKTERLY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking EKTERLY.
  • Have liver problems.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking EKTERLY with certain other medicines can cause side effects or affect how well EKTERLY or the other medicines work. Especially tell your healthcare provider if you take any of the following, as their use with EKTERLY is not recommended: itraconazole, phenytoin, efavirenz.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

What are the possible side effects of EKTERLY?

The most common side effects of EKTERLY include headache. For more information, ask your healthcare provider or pharmacist. Talk to your doctor for medical advice about side effects.

You are encouraged to report side effects related to KalVista products by calling 1-855-258-4782. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information, including Patient Information.